Dr. Reddys Laboratories Ltd.

BSE: 500124 | NSE: DRREDDY
Mid Cap | Pharmaceuticals & Drugs
1234.60
-10.90 (-0.88%)
< Home < Back

Dr. Reddy's Laboratories launches Ertapenem for Injection

Date: 12-05-2021

Dr. Reddy's Laboratories has launched Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of INVANZ (ertapenem for injection) for injection, 1 g/vial approved by the US Food and Drug Administration (USFDA).

The company’s Ertapenem for Injection, 1 g/vial, is available in packs of 10 vials per carton. The INVANZ brand and generic market had US sales of around $205 million MAT for the most recent twelve months ending in March 2021 according to IQVIA Health.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.